Advertisement Bristol-Myers to sell ConvaTec - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bristol-Myers to sell ConvaTec

Bristol-Myers Squibb has signed a definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII and Avista Capital Partners for approximately $4.1 billion.

The consideration is subject to adjustments based on ConvaTec’s audited 2007 financial statements and closing working capital. The closing, which is subject to customary regulatory approvals, is anticipated in the third quarter of 2008.

Nordic Capital and funds associated with Avista have severally guaranteed the obligations of the newly formed purchaser under the purchase agreement.

The purchaser has entered into a fully committed loan agreement which provides for funding by the lenders with no material conditions other than the conditions under the purchase agreement and customary conditions relating to the delivery of closing documents and financial information as well as conditions related to the status of the purchaser.